Original Contribution | Published:

Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis

American Journal of Gastroenterology volume 97, pages 575583 (2002) | Download Citation

Subjects

Abstract

OBJECTIVES: Esomeprazole, the S isomer of omeprazole, has been shown to have higher healing rates of erosive esophagitis than omeprazole. This study compared esomeprazole with lansoprazole for the healing of erosive esophagitis and resolution of heartburn.

METHODS:

This United States multicenter, randomized, double blind, parallel group trial was performed in 5241 adult patients (intent-to-treat population) with endoscopically documented erosive esophagitis, which was graded by severity at baseline (Los Angeles classification). Patients received 40 mg of esomeprazole (n = 2624) or 30 mg of lansoprazole (n = 2617) once daily before breakfast for up to 8 wk. The primary efficacy endpoint was healing of erosive esophagitis at week 8. Secondary assessments included proportion of patients healed at week 4, resolution of investigator-recorded heartburn, time to first and time to sustained resolution of patient diary-recorded heartburn, and proportion of heartburn-free days and nights.

RESULTS:

Esomeprazole (40 mg) demonstrated significantly higher healing rates (92.6%, 95% CI = 91.5–93.6%) than lansoprazole (30 mg) (88.8%, 95% CI = 87.5–90.0%) at week 8 (p = 0.0001, life-table estimates, intent-to-treat analysis). A significant difference in healing rates favoring esomeprazole was also observed at week 4. The difference in healing rates between esomeprazole and lansoprazole increased as baseline severity of erosive esophagitis increased. Sustained resolution of heartburn occurred faster and in more patients treated with esomeprazole. Sustained resolution of nocturnal heartburn also occurred faster with esomeprazole. Both treatments were well tolerated.

CONCLUSIONS:

Esomeprazole (40 mg) is more effective than lansoprazole (30 mg) in healing erosive esophagitis and resolving heartburn. Healing rates are consistently high with esomeprazole, irrespective of baseline disease severity.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    . Epidemiology and natural history of gastro- oesophageal reflux disease. Digestion 1992;51:24–29.

  2. 2.

    , Gastroesophageal reflux disease. Curr Opin Gastroenterol 1998;14:326–333.

  3. 3.

    , , , et al. The Second Canadian Gastroesophageal Reflux Disease Consensus: Moving forward to new concepts. Can J Gastroenterol 1998;12:551–556.

  4. 4.

    . The pathogenesis of gastroesophageal reflux disease: The relationship between epithelial defense, dysmotility, and acid exposure. Am J Gastroenterol 1997;92:3S–7S.

  5. 5.

    , , , et al. Endoscopic assessment of oesophagitis: Clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999;45:172–180.

  6. 6.

    Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: A systematic overview. Can J Gastroenterol 1997;11(suppl B):66B–73B.

  7. 7.

    , , , et al. Critical issues in the management of gastroesophageal reflux disease. Eur J Gastroenterol Hepatol 1995;7:577–586.

  8. 8.

    , , , et al. The diagnosis and treatment of gastroesophageal reflux disease in a managed care environment: Suggested disease management guidelines. Arch Intern Med 1996;156:477–484.

  9. 9.

    , , , et al. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group. Am J Gastroenterol 1996;91:1749–1757.

  10. 10.

    , , , et al. Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Results of a Scandinavian multicentre trial. Scand J Gastroenterol 1993;28:224–228.

  11. 11.

    , . Rapid symptom relief in reflux oesophagitis: A comparison of lansoprazole and omeprazole. Aliment Pharmacol Ther 1996;10:757–763.

  12. 12.

    , , , et al. Pantoprazole versus omeprazole in the treatment of reflux esophagitis. Acta Med Croatica 1999;53:79–82.

  13. 13.

    , , , et al. Pantoprazole and omeprazole in the treatment of reflux oesophagitis: A European multicentre study. Aliment Pharmacol Ther 1995;9:667–671.

  14. 14.

    , , , et al. Double-blind comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group. Aliment Pharmacol Ther 1999;13:49–57.

  15. 15.

    , , , et al. A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: A multicentre trial. Aliment Pharmacol Ther 1995;9:321–326.

  16. 16.

    , , . Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastrooesophageal reflux disease. Scand J Gastroenterol 2000;35:1245–1250.

  17. 17.

    , , , et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: A randomized controlled trial. Am J Gastroenterol 2001;96:656–665.

  18. 18.

    , , , et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: A randomised controlled trial. Aliment Pharmacol Ther 2000;14:1249–1258.

  19. 19.

    , , , et al. The endoscopic assessment of esophagitis: A progress report on observer agreement. Gastroenterology 1996;111:85–92.

  20. 20.

    , , . Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis. Aliment Pharmacol Ther 2001;15:227–231.

  21. 21.

    , , First comparison of pantoprazole versus lansoprazole in hospital and private practice patients with reflux esophagitis. Gastroenterology 1998;114:A110–A111.

  22. 22.

    , , Lansoprazole 30 mg versus omeprazole 40 mg in the treatment of reflux oesophagitis grade II, III and IVa (a Dutch multicentre trial). Dutch Study Group. Eur J Gastroenterol Hepatol 1996;8:1101–1106.

  23. 23.

    , , , et al. Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: The U.S. Multicenter Study. Gastroenterology 1992;102:109–118.

  24. 24.

    , , , et al. A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Multicentre Investigational Group. Aliment Pharmacol Ther 1995;9:25–31.

  25. 25.

    , , , et al. Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. UK Lansoprazole Clinical Research Group. Aliment Pharmacol Ther 1995;9:145–151.

  26. 26.

    , , , et al. Efficacy and safety of pantoprazole in patients with gastroesophageal reflux disease using an intravenous-oral regimen. Austrian Intravenous Pantoprazole Study Group. Hepatogastroenterology 1999;46:1809–1815.

  27. 27.

    , , , et al. Clinical superiority of pantoprazole over ranitidine in the treatment of reflux esophagitis grade II and III. A prospective, double-blind, double-placebo study. Mexican clinical experience. Mexican Pantoprazole Study Group. Rev Gastroenterol Mex 1998;63:11–16.

  28. 28.

    , , , et al. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 1997;32:965–973.

  29. 29.

    , , , et al. Esomeprazole provides improved acid control versus omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000;14:861–867.

  30. 30.

    , , , et al. Esomeprazole 40 mg provides more effective acid control than lansoprazole 30 mg. Gastroenterology 2000;118:A20.

  31. 31.

    , , , et al. Esomeprazole (E) 40 mg provides more effective acid control than pantoprazole (P) 40 mg. Gastroenterology 2000;118:A22.

  32. 32.

    , , , et al. Esomeprazole 40 mg provides more effective acid control than rabeprazole 20 mg. Gut 2000 2000;47(suppl III):A63.

  33. 33.

    Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996;31:9–28.

Download references

Acknowledgements

We gratefully acknowledge the assistance of Clara S. Hwang, M.S., and Ola Junghard, Ph.D., with statistical analyses; the study coordinators at the investigation sites; and all of the principal investigators. This study was supported by a grant from AstraZeneca LP, Wayne, PA.

The esomeprazole study investigators: D. R. Aarons; D. Abrahm, Newport Beach Orange Coast Endoscopy Center; J. Alcorn, Southwest GI Associates, PC; M. Ali; E. Ang; A. Arora, Sierra Medical Research; D. Avner; A. Bailey, Midstate Medical Building; L. Bank, United Medical Associates; C. F. Barish, Wake Research Associates; G. M. Barton, Arkansas Gastroenterology; I. Bassan; J. Beckman; J. Beckwith, M. D. S. Harris; T. Ben-Menachem, Henry Ford Health System; M. Bennett, Medical Associates Research Group; R. W. Bennetts, Northwest Gastroenterology Clinic; C. Berggreen; P. Berggreen; A. Berlin, Institute of HealthCare Assessment, Inc.; W. R. Berry, Longmont Clinic; T. D. Bianchi, Community Medical Arts Center; P. C. Bird, Research Associates of Norman, Inc.; D. Blalock, Lynn Health Science Institute; B. Bleau, Tacoma Digestive Disease Center; V. A. Botoman, Cleveland Clinic Florida; W. C. Bray, Digestive Health Specialists, PA; J. Breiter, Center for Medical Research LLC; M. Brown, Rush-Presbyterian/St. Luke's Medical Center; K. Buch; J. Caldwell; A. Caos; S. L. Carpenter, Southern Digestive & Liver Disease Institute; D. R. Cave, St. Elizabeth's Medical Center of Boston; A. Chak; T. Chami; R. Chasen, Maryland Digestive Disease Center; E. Cheng, VAMC Northport; D. Chua, Research Concepts, Inc.; N. Cirillo, Western Carolina Digestive Disease Center; L. Cohen, NYGA; C. Colip; C. B. Davis, Monroe Clinic; E. P. DeNoia, Healthcare Discoveries; K. DeVault, Mayo Clinic Jacksonville; P. Dharmarajah; M. R. Dosch, ICSL Clinical Studies; D. W. Dozer, Discovery Research International; M. Draelos, Cornerstone Research Care; S. L. Duckor; C. Eberhart, Doctor's Clinic Research Department; G. Eisen, Vanderbilt University Medical Center; M. Eisner, Clinical Research Division; D. Eskreis, Long Island Clinical Research Associates; P. Eweje, Johnson Digestive Disease Group; C. Fausel, The Oregon Clinic GI; S. Feldman, Gastroenterology Associates of Fairfield County; R. S. Fisher, Temple University Hospital; J. D. Fitterer; I. Flax, Breco Research, Inc.; C. E. Forsmark, University of Florida; F. C. Fowler; S. Frank; B. Freilich; S. Gaddam; L. Gelrud, GI Research; M. Georgetson, Guthrie Clinic, Ltd.; G. D. Gibbons, Remington-Davis, Inc.; L. I. Gilderman, University Clinical Research, Inc.; H. A. Giller, Digestive and Liver Disease Consultants, PC; J. Goff, Western States Clinical Research, Inc.; M. Goldhamer, Michael Goldhamer, MD, Inc.; J. Goldstein, Brachfeld Medical Associates; M. J. Goldstein, Long Island Gastrointestinal Research Group; P. Gonzalez; D. G. Gordon, Danbury Internal Medicine Associates, P.C.; M. Gorsky, Gastrointestinal and Liver Disease Consultants; P. R. Guenthner, The Linder Clinical Trial Center; M. S. Gurney; R. Hansen, Arapahoe Gastroenterology; R. Hardi, Metropolitan Gastroenterology Group, P.C.; A. Harrison; V. Hee, The Vancouver Clinic Inc. PS; E. A. Heller, Digestive Disease Associates of Rockland; E. Hirsh, Gastroenterology Consultants PC; J. Hsu, The ViaHealth Genesee Hospital; J. Hurtado, Advanced Therapeutic Research; D. James; V. Jayanty, Houston Endo. & Research Ctr., Inc.; J. E. Johanson, Rockford Gastroenterology Associates, Ltd.,; D. Johnson, Digestive and Liver Disease Specialists, Ltd.; J. H. Johnson, Mississippi Center for Clinical Research, LLC; R. B. Johnson, Sharp-Rees-Stealy Medical Group; J. Johnston; J. Jolley; J. Jones, Green Clinic; R. S. Jones, Little Rock Diagnostic Clinic; S. Kailas; M. Kajani; R. Kamyar, Institute of HealthCare Assessments, Inc.; R. Kaplan, LeBauer Research Associates, PA; P. Kiyasu, The Portland Clinic, LLP; T. C. Klein, Heartland Research Associates, LLC; R. Knox, Murfreesboro Medical Clinic; R. A. Kommor, Health Advance; K. Kormis; T. O. Kovacs, CURE Clinic/West LA VAMC; G. Koval, West Hills Gastroenterology Associates, PC; R. Krause, Clinsearch; S. Krumholz, Waterside Clinical Research Services Inc.; D. Kruss; F. Kucer, Upper Bucks Medical Arts Building; L. Laine, USC School of Medicine; M. Lamet; F. Lanza; J. S. Leavitt; P. J. Lebovitz, Allegheny Center for Digestive Health; M. S. LeVine, SouthEast Research Associates; R. Lindenberg; J. Lowe; D. Maccini; M. Madan, Rochester Clinical Research; H. N. Maimon, Targeted Research Inc.; S. Malhotra, GI and Hepatology Associate; D. Mangels, TQM Research Inc.; S. P. Marcuard, Carolina Research Center; R. D. Marks, Alabama Digestive Research Center; P. N. Maton, Digestive Diseases Research Institute; A. McElroy, Multi-Specialty Clinical Research; J. Medoff, Medoff Medical/Vital Research; P. B. Meier, VAMC GI Section; T. E. Mendolia; P. J. Milman; P. B. Miner, Oklahoma Foundation for Digestive Research; B. M. Miskin, Palm Beach Research Center; S. M. Mitchell, GI Associates of Colorado Springs, LLP; V. C. Motaparthy; S. E. Moussa; R. V. Movva, Midwest Clinical Research Associates; J. Mueller, Coastal Medical Group Ltd.; V. Narayen, Digestive Disease Associates; I. Newell, North Carolina Clinical Research; M. Noar, Endoscopic Microsurgery Associates; J. S. Novick, Charm City Research LLC; H. Offenberg, Gainsville Clinical Research Center; B. F. Overholt; D. J. Pambianco, Charlottesville Medical Research; P. M. Pardoll, Center for Digestive Diseases; R. Patel; W. Pearce, Rainier Clinical Research Center, Inc.; R. Peterson; J. M. Polito, Albany Gastroenterology Consultants; J. W. Popp, Carolina Clinical Research, Inc.; J. Poulos; V. Pratha, Clinical Applications Laboratories; J. M. Provenza, Louisiana Research Center, LLC; G. S. Raju, University of Kansas Medical Center; C. Randall, Gastroenterology Clinic of San Antonio; R. Rapier, Southern California Permanente Medical Center; J. Reddy; D. Rex, Indiana University Hospital; M. Reynolds, Radiant Research; D. Ricci; D. S. Riff, AGMG Clinical Research; M. A. Ringold, Medical Associates of Southwest Virginia; R. E. Ringrose; D. Ritt; M. Rodriguez; A. Rosen; D. J. Rosenberg; M. Z. Rosenberg, Research Foundation of America; W. Ross; V. Rustgi, Metropolitan Research Center; J. Sabel, South Denver Gastroenterology, PC; L. S. Saco, Watson Clinic LLP; S. Safavi, Doctors Research Associates of Maryland; M. Safdi, Consultants for Clinical Research; L. Y. Salazar; J. R. Saltzman, Brigham & Women's Hospital; B. A. Salzberg; B. Sanders; J. Santoro, Atlantic Gastroenterology Associates; P. Schleinitz; C. Schmitt, Southeastern Clinical Research; J. Schneier; M. I. Schulman; H. I. Schwartz, Miami Research Associates, Inc.; J. L. Schwartz, Northwestern Gastroenterologists, S.C.; M. E. Schwartz; A. R. Shah, Calvert Medical Office Building; U. K. Shah, Philip J. Bean Medical Center; R. Shaker; P. Sharma, Department of Veterans Affairs Medical Center; B. N. Shivakumar; D. Siegel; B. Silverman, Memorial Clinic Research Center; T. Simmons, West Gastroenterology Group; W. J. Snape, Long Beach Gastroenterology Associates; T. Sobieski; H. Sperber, Health Advance Institute, Inc.; G. A. Spiegelman; E. Spiotta; D. Stanton; W. Stassen, Radiant Research-Austin; R. Steller, Long Island GI Group, PC; W. Stern, Gastrointestinal Research Associates; R. J. Stitcher, Gastroenterology Specialties, PC; L. R. Strong; J. L. Taunk; R. W. Tobin; A. Tuch, Crozer Chester Medical Center; J. Turse, Health Advance Institute; N. B. Vakil, Sinai Samaritan Medical Center; R. Vender; J. B. Wagonfeld, Digestive Health Specialists; J. L. Wang; D. Weinberg, Thomas Jefferson University; L. M. Weiss; G. J. Wiener; S. Wilkofsky, Radiant Research Dallas; J. Winder, Toledo Center for Clinical Research; B. D. Winston, Houston Medical Research Associates; P. C. Witt, Greeley Medical Clinic; J. Wo, University of Louisville Health Sciences Center; R. A. Wohlman, Northwest Gastroenterology; J. Wolosin; L. D. Wruble, Memphis Gastroenterology Group, PC; M. Young, Carl Hayden VA; F. Zwas.

Author information

Affiliations

  1. Department of Gastroenterology and Hepatology, Medical University of South Carolina, Charleston, South Carolina, USA

    • Donald O Castell
  2. Division of Gastroenterology and Hepatology, Northwestern University Medical School, Chicago, Illinois, USA

    • Peter J Kahrilas
  3. Department of Gastroenterology, Cleveland Clinic Foundation, Cleveland, Ohio, USA

    • Joel E Richter
  4. Division of Gastroenterology, University of Wisconsin Medical School, Milwaukee, Wisconsin, USA

    • Nimish B Vakil
  5. Division of Gastroenterology, Eastern Virginia School of Medicine, Norfolk, Virginia, USA

    • David A Johnson
  6. AstraZeneca, Wayne, Pennsylvania, USA

    • Seth Zuckerman
    • , Wendy Skammer
    •  & Jeffrey G Levine

Authors

  1. Search for Donald O Castell in:

  2. Search for Peter J Kahrilas in:

  3. Search for Joel E Richter in:

  4. Search for Nimish B Vakil in:

  5. Search for David A Johnson in:

  6. Search for Seth Zuckerman in:

  7. Search for Wendy Skammer in:

  8. Search for Jeffrey G Levine in:

Corresponding author

Correspondence to Donald O Castell.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1111/j.1572-0241.2002.05532.x